立体定向消融放疗用于未接受系统治疗的寡转移性肾癌
这项前瞻性II期单臂试验评估立体定向消融放疗(SAbR)对未接受系统治疗的寡转移性肾细胞癌(RCC)的纵向疾病控制和生活质量(QOL)保持能力。23例患者接受SAbR,1年免于系统治疗率为91.3%(95%CI 69.5–97.8),超过预设60%基准。结论认为SAbR与有意义的纵向疾病控制相关并保持QOL,支持进一步评估。
要点
- 1年免于系统治疗率为91.3%(95%CI 69.5–97.8),超过预设60%基准。
- 1年无进展生存率为82.6%(95%CI 60.1–93.1),局部控制率为100%。
- 无3/4级毒性,但1例在SAbR后3个月接受检查点抑制剂治疗期间死于免疫相关结肠炎,不能排除SAbR的影响。
核心结论
- SAbR用于寡转移性RCC与有意义的纵向疾病控制相关,同时保持QOL。
- 这些数据支持进一步评估SAbR用于未接受系统治疗的寡转移性RCC。
研究设计与样本
- 前瞻性II期单臂试验,纳入转移灶不超过3个的颅外转移RCC患者,对所有 upfront 及后续(如适用)转移灶纵向给予SAbR。
- 样本量为23例患者,共接受33个初始和57个总部位的SAbR。
- 主要目标为采用Clopper和Pearson方法检验超过60%的患者免于系统治疗超过1年。
主要发现
- 中位随访21.7个月(四分位距16.3–30.3)。
- 1年免于系统治疗率为91.3%(95%CI 69.5–97.8)。
- 1年无进展生存率为82.6%(95%CI 60.1–93.1),局部控制率为100%。
- QOL基本未受影响;无3/4级毒性,但1例在SAbR后3个月接受后续检查点抑制剂治疗期间死于免疫相关结肠炎,不能排除SAbR的影响。
- 1年总生存率为95.7%(95%CI 72.9–99.4),1年癌症特异性生存率为100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence-based guidelines for the management of systemic therapy-naïve oligometastatic renal cell carcinoma (RCC) are lacking. OBJECTIVE: To evaluate the potential of stereotactic ablative radiotherapy (SAbR) to provide longitudinal disease control while preserving quality of life (QOL) in patients with systemic therapy-naïve oligometastatic RCC. DESIGN, SETTING, AND PARTICIPANTS: RCC patients with three or fewer extracranial metastases were eligible. SAbR was administered longitudinally to all upfront and, as applicable, subsequent metastases. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: This prospective phase II single-arm trial was powered to achieve a primary objective of freedom from systemic therapy for >1 yr in >60% of patients (using the Clopper and Pearson methodology). Secondary endpoints included progression-free survival (PFS), defined as the time from first SAbR to progression not amenable to SAbR (local failure at SAbR-treated sites, new metastases not amenable to SAbR, more than three new metastases, or brain metastases); patient-reported QOL metrics; local control (LC) rates; toxicity; cancer-specific survival (CSS); and overall survival (OS). RESULTS AND LIMITATIONS: Twenty-three patients received SAbR to 33 initial and 57 total sites. The median follow-up was 21.7 mo (interquartile range 16.3-30.3). Exceeding the prespecified 60% benchmark, freedom from systemic therapy at 1 yr was 91.3% (95% confidence interval [CI]: 69.5, 97.8). One-year PFS was 82.6% (95% CI: 60.1, 93.1). QOL was largely unaffected. LC was 100%. There were no grade 3/4 toxicities, but there was one death due to immune-related colitis 3 mo after SAbR while on subsequent checkpoint inhibitor therapy, where a SAbR contribution could not be excluded. One-year OS was 95.7% (95% CI: 72.9, 99.4); one-year CSS was 100%. CONCLUSIONS: SAbR for oligometastatic RCC was associated with meaningful longitudinal disease control while preserving QOL. These data support further evaluation of SAbR for systemic therapy-naïve oligometastatic RCC. PATIENT SUMMARY: Sequential stereotactic radiation therapy can safely and effectively control metastatic kidney cancer with limited spread for over a year without compromising patients' quality of life.
引用
- Hannan R, Christensen M, Christie A, et al. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. Eur Urol Oncol. 2022. PMID: 35985982. doi:10.1016/j.euo.2022.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。